2010Cancer Chemotherapy and PharmacologyRequires access

Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial

Peter Gibbs, Philip R. Clingan, Vinod Ganju, Andrew H. Strickland, Shirley Wong, Niall Christopher Tebbutt, Craig R. Underhill, Richard M. Fox, Steven P. Clavant, Jenny Yin‐Yan Leung, Minh Pho, Tracey J. Brown

Open publisher page 54 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 54 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Irinotecan, Medicine, Internal medicine, Colorectal cancer, Camptothecin, Toxicity, Gastroenterology, Oncology

Related papers

Back to paper searchBrowse research topicsOriginal source
Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial — Research Paper | ScholarLens